Design and Rationale of the RE-DUAL PCI Trial : A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting

Published on Aug 26, 2016in Clinical Cardiology2.248
· DOI :10.1002/CLC.22572
Christopher P. Cannon168
Estimated H-index: 168
(Harvard University),
Savion Gropper7
Estimated H-index: 7
(Boehringer Ingelheim)
+ 13 AuthorsStefan H. Hohnloser89
Estimated H-index: 89
(Goethe University Frankfurt)
Sources
Abstract
Antithrombotic management of patients with atrial fibrillation (AF) undergoing coronary stenting is complicated by the need for anticoagulant therapy for stroke prevention and dual antiplatelet the ...
📖 Papers frequently viewed together
853 Citations
1,181 Citations
3,924 Citations
References45
Newest
15 CitationsSource
#1Glenn N. LevineH-Index: 32
#2Eric R. Bates (UM: University of Michigan)H-Index: 73
Last. Sidney C. SmithH-Index: 171
view all 17 authors...
Jonathan L. Halperin, MD, FACC, FAHA, Chair Glenn N. Levine, MD, FACC, FAHA, Chair-Elect Sana M. Al-Khatib, MD, MHS, FACC, FAHA Kim K. Birtcher, PharmD, MS, AACC Biykem Bozkurt, MD, PhD, FACC, FAHA Ralph G. Brindis, MD, MPH, MACC, FAHA Joaquin E. Cigarroa, MD, FACC Lesley H. Curtis, PhD,
1,007 CitationsSource
Patients with atrial fibrillation needing stents pose one of the greatest challenges in cardiovascular medicine [(1)][1]. The atrial fibrillation generally warrants anticoagulation, and dual antiplatelet therapy is the established standard of care for patients with stents [(2–4)][2]. The
17 CitationsSource
#2Michael Maeng (Aarhus University Hospital)H-Index: 52
Last. Nikolaus Sarafoff (LMU: Ludwig Maximilian University of Munich)H-Index: 12
view all 17 authors...
Abstract Background Patients receiving oral anticoagulation (OAC) who undergo drug-eluting stent (DES) implantation require additional dual antiplatelet therapy with aspirin and clopidogrel. Such triple therapy confers an elevated bleeding risk, and its optimal duration is not known. Objectives The goal of this study was to evaluate whether shortening the duration of clopidogrel therapy from 6 months to 6 weeks after DES implantation was associated with a superior net clinical outcome in patient...
307 CitationsSource
#1David J. Graham (CDER: Center for Drug Evaluation and Research)H-Index: 35
#2Marsha E. Reichman (CDER: Center for Drug Evaluation and Research)H-Index: 15
Last. Jeffrey A. Kelman (Centers for Medicare and Medicaid Services)H-Index: 20
view all 13 authors...
Background— The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established. Methods and Results— We formed new-user cohorts of propensity score–matched elderly patients enrolled in Medicare who initiated dabigatran or warfarin for treatment of nonvalvular atrial fibrillation between October 2010 and December 2012. Among 134 414 patients with 37 587 person-years of follow-up, there were 2715 primary outco...
506 CitationsSource
#1Laura Mauri (Harvard University)H-Index: 95
#2Dean J. KereiakesH-Index: 108
Last. Joseph M. Massaro (BU: Boston University)H-Index: 120
view all 22 authors...
0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P = 0....
1,251 CitationsSource
#2L. Samuel WannH-Index: 29
#3Joseph S. AlpertH-Index: 107
Last. Clyde W. YancyH-Index: 121
view all 16 authors...
Jeffrey L. Anderson, MD, FACC, FAHA, Chair Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect Nancy M. Albert, PhD, RN, FAHA Biykem Bozkurt, MD, PhD, FACC, FAHA Ralph G. Brindis, MD, MPH, MACC Mark A. Creager, MD, FACC, FAHA[#][1] Lesley H. Curtis, PhD, FAHA David DeMets, PhD[#][1] Robert A
5,972 CitationsSource
#1Gregory Y.H. Lip (University of Birmingham)H-Index: 195
#2Stephan WindeckerH-Index: 150
Last. José Luis ZamoranoH-Index: 82
view all 26 authors...
Atrial fibrillation (AF) confers a substantial risk of mortality and morbidity from stroke and thrombo-embolism, and this common cardiac arrhythmia represents a major healthcare burden in Europe.1 Stroke prevention is central to the management of AF patients, with the 2012 focused update of the European Society of Cardiology (ESC) guidelines2 recommending oral anticoagulation (OAC) using well-controlled adjusted dose vitamin K antagonists (VKAs, e.g. warfarin) or non-VKA oral anticoagulants (NOA...
448 CitationsSource
#1Stuart J. Connolly (McMaster University)H-Index: 140
#2Lars WallentinH-Index: 150
Last. Salim YusufH-Index: 247
view all 3 authors...
To the Editor: Boehringer Ingelheim recently conducted a targeted review of the 1387 deaths that occurred during the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial,1 which evaluated the effects of two doses of dabigatran, as compared with warfarin, on rates of stroke or systemic embolism and major bleeding. Also included in this review were the deaths of 6 patients who did not undergo randomization and 10 deaths that occurred after the end of the study. This review was ...
40 CitationsSource
3,452 CitationsSource
Cited By54
Newest
#1Javad Sharifi-Rad (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 4
#2Natália Cruz-Martins (University of Porto)H-Index: 2
Last. Farukh Sharopov (Tajik Academy of Sciences)H-Index: 22
view all 0 authors...
Coumarins belong to the benzopyrone family commonly found in many medicinal plants. Natural coumarins demonstrated a wide spectrum of pharmacological activities, including anti-inflammatory, anticoagulant, anticancer, antibacterial, antimalarial, casein kinase-2 (CK2) inhibitory, antifungal, antiviral, Alzheimer’s disease inhibition, neuroprotective, anticonvulsant, phytoalexins, ulcerogenic, and antihypertensive. There are very few studies on the bioavailability of coumarins; therefore, further...
Source
#1David Eccleston (University of Melbourne)H-Index: 13
#2Joseph M. Kim (Brigham and Women's Hospital)
Last. Christopher P. Cannon (Brigham and Women's Hospital)H-Index: 168
view all 13 authors...
Background The RE-DUAL PCI trial demonstrated that in patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual therapy with dabigatran and a P2Y12 inhibitor, either clopidogrel or ticagrelor, reduced the risk of bleeding without an increased risk of thromboembolic events as compared to triple therapy with warfarin in addition to a P2Y12 inhibitor and aspirin. What remains unclear is whether this effect is consistent between males and females un...
Source
#1Benjamin E Peterson (Brigham and Women's Hospital)H-Index: 4
#2Deepak L. Bhatt (Brigham and Women's Hospital)H-Index: 167
Last. Christopher P. Cannon (Brigham and Women's Hospital)H-Index: 168
view all 16 authors...
Abstract Objectives The aim of this study was to explore the early versus late benefits and risks of dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial. Background Patients with atrial fibrillation who undergo percutaneous coronary intervention are at increased risk fo...
3 CitationsSource
#1Pierre Sabouret (University of Paris)H-Index: 11
#2Michael P. Savage (Thomas Jefferson University)H-Index: 22
Last. Francesco Costa (UNIME: University of Messina)H-Index: 21
view all 4 authors...
: Patients with coronary artery disease (CAD) presenting with acute coronary syndrome or undergoing coronary stenting are indicated to treatment with dual antiplatelet therapy (DAPT) combining aspirin with a P2Y12 receptor inhibitor. The management of patients with CAD who present with a complex clinical profile due to multiple comorbidities, and/or undergoing complex interventional procedures, remains challenging as a high risk for both ischemic and bleeding events is often present; hence, the ...
1 CitationsSource
#1Shujuan Zhao (Zhengzhou University)H-Index: 1
#2Xuejiao Hong (Zhengzhou University)H-Index: 1
Last. Peizhi Ma (Zhengzhou University)H-Index: 2
view all 6 authors...
Combined antithrombotic regimens for atrial fibrillation (AF) patients with coronary artery disease, particularly for those who have acute coronary syndrome (ACS) and/or are undergoing percutaneous coronary intervention (PCI), presents a great challenge in the real-world clinical scenario. Conventionally, a triple antithrombotic therapy (TAT), which consists of combined oral anticoagulant therapy to prevent systemic embolism or stroke along with dual antiplatelet therapy to prevent coronary arte...
Source
#1Francesco Costa (UNIME: University of Messina)H-Index: 21
#2Marco Valgimigli (University of Bern)H-Index: 117
Last. Christopher P. Cannon (Brigham and Women's Hospital)H-Index: 168
view all 11 authors...
Aims Patients with atrial fibrillation undergoing coronary intervention are at higher bleeding risk due to the concomitant need for oral anticoagulation and antiplatelet therapy. The RE-DUAL PCI trial demonstrated better safety with dual antithrombotic therapy (DAT: dabigatran 110 or 150 mg bid, clopidogrel or ticagrelor) compared to triple antithrombotic therapy (TAT: warfarin, clopidogrel or ticagrelor, and aspirin). We explored the impact of baseline bleeding risk based on the PRECISE-DAPT sc...
3 CitationsSource
#1Raffaele De Caterina (UniPi: University of Pisa)H-Index: 16
#2Antonio Procopio (University of Chieti-Pescara)H-Index: 22
Last. InvestigatorsH-Index: 11
view all 18 authors...
BACKGROUND: Body mass index (BMI) affects drug levels of nonvitamin K antagonist oral anticoagulants. We sought to assess whether BMI affected outcomes in the RE-DUAL PCI trial. METHODS: RE-DUAL PCI (NCT02164864) evaluated the safety and efficacy of a dual antithrombotic therapy regimen using dabigatran (110 or 150 mg twice daily [BID] and a P2Y12 platelet antagonist), in comparison with "triple therapy" with warfarin, aspirin, and a P2Y12 platelet inhibitor, in 2725 patients with atrial fibrill...
Source
#1Jose C. Nicolau (USP: University of São Paulo)H-Index: 68
#2Deepak L. Bhatt (Brigham and Women's Hospital)H-Index: 167
Last. Christopher P. Cannon (Brigham and Women's Hospital)H-Index: 168
view all 13 authors...
Background and objective In patients with atrial fibrillation following percutaneous coronary intervention, if a proton pump inhibitor is used, could that allow the use of warfarin triple therapy, or is there additional reduction in bleeding while using it with dual therapy? Methods The RE-DUAL PCI trial randomized 2725 patients with atrial fibrillation post-percutaneous coronary intervention to dabigatran dual therapy (110 or 150 mg twice daily, with clopidogrel or ticagrelor) or warfarin tripl...
Source
#1Nan WangH-Index: 1
#2Lu Chen (Tianjin Medical University)H-Index: 4
view all 7 authors...
Dabigatran etexilate (DABE) is a direct oral anticoagulant (DOAC) and may be combined with ticagrelor, a P2Y12 inhibitor with antiplatelet effects. This combination of antiplatelet drugs and anticoagulants would increases the risk of bleeding in patients. In addition, the potential drug interaction may further increase the risk of bleeding. At present, there is scarce research to clarify the results of the interaction between the two. Therefore, we conducted this study to identify the potential ...
Source
#1Francesco Costa (UNIME: University of Messina)H-Index: 21
#2David van Klaveren (Erasmus University Medical Center)H-Index: 5
view all 12 authors...
Abstract The originally-proposed PRECISE-DAPT score is a 5-item risk score supporting decision-making for dual antiplatelet therapy1 duration after PCI. It is unknown if a simplified version of the score based on 4 factors (age, hemoglobin, creatinine clearance, prior bleeding), and lacking white-blood cell count, retains potential to guide DAPT duration. The 4-item PRECISE-DAPT was used to categorize 10,081 patients who were randomized to short (3–6 months) or long (12–24 months) DAPT regimen a...
7 CitationsSource